Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System

Clinical trial NCT04561557 · RECRUITING

Trial details

NCT number: NCT04561557
Sponsor: Tongji Hospital
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Autoimmune Diseases Autoimmune Diseases of the Nervous System Neuromyelitis Optica Spectrum Disorder Myasthenia Gravis Chronic Inflammatory Demyelinating Polyradiculoneuropathy Idiopathic Inflammatory Myopathies Multiple Sclerosis Autoimmune Encephalitis Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)POEMS Syndrome

Start date: 2020-09-22
Primary completion: 2027-02-22
Enrollment: 36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.